Pharma positions itself for 2026 amid an evolving US landscape
After President Donald Trump’s administration took office in early 2025, a series of policy changes have directly impacted the pharma …
Post
-
-
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push
BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies …
-
UK approves Gilead’s twice-yearly HIV PrEP drug
Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering …
-
Trump administration ties pricing deals with another nine pharma companies
Nine big pharma companies have reached agreements with the Trump administration to lower prices for certain drugs in the US …
-
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, 10mg, 15mg, …
-
AstraZeneca pulls Andexxa from US market after post-marketing fatalities
AstraZeneca has pulled its anticoagulant therapy, Andexxa (recombinant coagulation factor Xa), from the US market after patient fatalities. This follows rising …
-
MEDIPOST, Teikoku Seiyaku partner for CARTISTEM commercialisation in Japan
MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem cell therapy for moderate …
-
Pharmaceutical Technology Excellence Awards 2025: Tech Mahindra
Tech Mahindra has built a broad presence across the life sciences value chain, from clinical and regulatory services through manufacturing …
-
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the pharmaceutical supply …
-
Nxera seeks schizophrenia programme buyer after Boehringer snub
Japan-based Nxera Pharma is seeking buyers for its Phase II-ready schizophrenia programme after Boehringer Ingelheim decided not to exercise a …
-
Takeda to seek approval of plaque psoriasis pill on Phase III trial data
Takeda’s once-daily oral plaque psoriasis (PsO) drug has met all its endpoints in two pivotal trials, with the company set …
-
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Eli Lilly’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA), orforglipron, has proven its efficacy as a maintenance therapy in patients …
-
MHRA launches call for evidence on AI regulation in UK healthcare sector
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a call for evidence seeking input from the healthcare …
-
J&J receives FDA approval for lung cancer therapy
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), …
-
FDA approves meningioma label warning on Pfizer’s contraceptive injection
The US Food and Drug Administration (FDA) has approved a label change to Pfizer’s injectable contraceptive, Depo-Provera (medroxyprogesterone acetate), which …
